Illuccix

Gozetotide, the active ingredient in Illuccix, is a pharmaceutical compound presented as an intravenous formulation for clinical use. It is being evaluated for potential therapeutic applications in specific patient populations and is supplied as a sterile solution for infusion.

GNH USA supplies Illuccix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Illuccix (gozetotide) is currently under clinical investigation, and no approved therapeutic indications have been publicly disclosed.

- Investigational: Under clinical evaluation for potential therapeutic benefit.

Adverse reaction information for gozetotide is limited, and a comprehensive safety profile has not been established.

Common Side Effects: - Not publicly disclosed.

Serious or Rare Side Effects: - Not publicly disclosed.

Given the limited public data, clinicians should exercise caution and follow standard intravenous medication safety practices. - Monitor patient: Observe for any infusion‑related reactions. - Assess renal function: Evaluate kidney status before administration. - Assess hepatic function: Evaluate liver status before administration. - Avoid use in known hypersensitivity: Discontinue if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Interaction data for gozetotide are not publicly available.

Major Interactions (Avoid): - Not publicly disclosed.

Moderate Interactions (Monitor Closely): - Not publicly disclosed.